Solid lipid nanoparticles (SLN) for controlled drug delivery

Müller, R.H.; Freitas, C.; Mühlen, A. Zur; Mehnert, W.

doi:10.1016/s0928-0987(97)86243-4

Cited by 125 publications

(131 citation statements)

References 1 publication

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, the drug can also be covalently attached to the surface or dispersed into the matrix. Nanoparticles are made from biocompatible and biodegradable materials such as polymers, either natural (e.g., gelatin, albumin) or synthetic (e.g., polylactides, polyalkylcyanoacrylates), or solid lipids (SLN®, NLC®) [36] in the body, the drug loaded in nanoparticles is usually released from the matrix by diffusion, swelling, erosion, or degradation.…”

Section: Introductionmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

Section: Introductionmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

show abstract

“…The later consist of a solid lipid matrix with a high content of liquid lipid (Radke, 2003). Both SLN and NLC possess a number of features advantageous for the topical route of application (Müller et al, 1995(Müller et al, , 2000d(Müller et al, , 2002Mehnert and Mäder, 2001). These carriers are composed of physiological and biodegradable lipids of low systemic toxicity and also low cytotoxicity (Müller et al, 1997).…”

Section: Introductionmentioning

confidence: 99%

Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery

Souto

Wissing

Barbosa

et al. 2004

International Journal of Pharmaceutics

591

206

View full text Add to dashboard Cite

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are colloidal carrier systems providing controlled release profiles for many substances. Clotrimazole-loaded SLN and NLC were prepared by the hot high pressure homogenization technique in order to evaluate the physical stability of these particles, as well as the entrapment efficiency of this lipophilic drug and its in vitro release profile. The particle size was analyzed by PCS and LD showing that the particles remained in their colloidal state during 3 months of storage at 4, 20 and 40 • C. For all tested formulations the entrapment efficiency was higher than 50%.The obtained results also demonstrate the use of these lipid nanoparticles as modified release formulations for lipophilic drugs over a period of 10 h.

show abstract

“…injection (Schwatrz et al, 1994). There are two basic homogenization techniques of homogenization for SLN, homogenization of melted lipids at elevated temperature (hot homogenization technique) and homogenization of a suspension of solid lipids at room temperature or below (cold homogenization technique) (Müller and Runge, 1998). In hot homogenization technique, the lipid matrix material is melted and drug can be incorporated by dissolving in the melted lipid.…”

Section: Manufacturing Methodsmentioning

confidence: 99%

“…40, Special issue (2010) ever, the release of most drug from fat emulsions is very fast (minutes) due to the distribution of the drug between oil droplets and the large volume of the blood. In early 1990s, a new idea was emerged; production of particles from solid lipids can combine the advantages of polymeric nanoparticles and fat emulsions (Müller and Runge, 1998). Particles from solid lipid possess a solid matrix allowing controlled drug release.…”

mentioning

confidence: 99%

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

Li¹,

Lim²,

Choi³

et al. 2010

Journal of Pharmaceutical Investigation

View full text Add to dashboard Cite

− Solid lipid nanoparticles (SLNs) have emerged to combine the advantages of polymeric nanoparticles and lipid emulsions in early 1990s. SLNs can present several desirable properties derived from the solid state core. When formulating SLNs, there should be careful considerations about the physical state of the inner solid lipid core and its polymorphism and supercooling behavior. In this review, SLNs were compared to lipid emulsion and emulsion of supercooled melt to understand the unusual behaviors compared to lipid emulsions and to have insights into stability and release mechanism. SLNs have been regarded as biocompatible system because lipids are usually well-tolerable ingredients than polymers. Several studies showed good tolerability of SLNs in terms of cytotoxicity and hemolysis. Similar to various other nanoparticulate drug delivery systems, SLNs can also change biodistribution of the incorporated drugs in a way to enhance therapeutic effect. Most of all, large scale production of SLNs was extablished wihtout using organic solvents. Although there is no SLN product in the market till date, several advantagious properties of SLNs and the progress we have seen so far would make commercial product of SLNs possible before long and encourage research community to apply SLN-based formulations for water-insoluble drugs.

show abstract

Solid lipid nanoparticles (SLN) for controlled drug delivery

Cited by 125 publications

References 1 publication

Present status of nanoparticle research for treatment of Tuberculosis

Present status of nanoparticle research for treatment of Tuberculosis

Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

Contact Info

Product

Resources

About